Low Testosterone Statistics in US 2026 | Rates, Symptoms & Key Men’s Health Facts

Low Testosterone in America 2026: What the Data Actually Tells Us

Low testosterone — clinically known as hypogonadism or testosterone deficiency (TD) — has emerged as one of the most widely discussed and simultaneously most underdiagnosed conditions in men’s health heading into 2026. Defined by the American Urological Association (AUA) as a total serum testosterone level below 300 ng/dL in combination with relevant symptoms, the condition affects a staggering proportion of American men across every age group. The most comprehensive recent data, drawn from the National Health and Nutrition Examination Survey (NHANES) and published in April 2026 in PMC/NIH, places overall testosterone deficiency prevalence among US adult men at 25.7% — meaning roughly one in four American men has clinically low testosterone levels when measured against the standard threshold. That figure covers a wide age range, and the numbers climb sharply with each passing decade: approximately 20% of men over 60 and 30% of men over 70 meet the diagnostic criteria for hypogonadism, according to the 2025 review published in Trends in Urology & Men’s Health (Wiley). At younger ages, the picture is more alarming than most people expect: testosterone deficiency has a documented prevalence of 20% among adolescent and young adult males aged 15–39, per research published in the Journal of Urology.

What is particularly striking about the 2026 state of low testosterone in the US is the convergence of two trends pulling in opposite directions. On one hand, the most recent NHANES data shows overall testosterone deficiency prevalence declining from 28.1% in 2011–2012 to 20.3% in 2021–2023, suggesting genuine population-level improvement. On the other hand, testosterone levels in young men have been falling on a time-dependent basis since at least 1999 — a decline that persists even after controlling for BMI and obesity — pointing to environmental, lifestyle, and systemic factors beyond aging alone. Against this backdrop, the treatment landscape has been reshaped by two landmark developments: the 2023 TRAVERSE trial, which studied 5,246 men and provided definitive cardiovascular safety data for testosterone replacement therapy (TRT), and the 2025 FDA removal of black box cardiovascular warnings on TRT products — a regulatory shift that has meaningfully changed how physicians approach prescribing and opened the door to significantly broader treatment. The result is a market where TRT prescriptions climbed from 7.3 million in 2019 to over 11 million in 2024, and the global TRT industry stands at $2.13 billion in 2026, growing at a sustained rate of 3.88% annually through the decade.

Interesting Facts About Low Testosterone in the US 2026

KEY LOW TESTOSTERONE FACTS AT A GLANCE — US 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 US Male Prevalence        ████████████████████████  25.7%
 Men Over 60 Affected      ████████████████          ~20%
 Men Over 70 Affected      ████████████████████      ~30%
 Young Men (15-39) Affected ████████████████         ~20%
 Only Treated              ██                         ~9%
 TRT Prescriptions (2024)  ████████████████████████  11M+
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: PMC/NIH (NHANES 2026), American Urological Association (AUA), Wiley Online Library, Journal of Urology, JACC, US Pharmacist, PLoS One, CBS News, Transparency Market Research

The breadth of these facts reveals a condition that is simultaneously common, undertreated, and rapidly changing in its clinical management. The only ~9% treatment rate among testosterone-deficient US men is perhaps the most clinically consequential number in the entire dataset: with 25.7% prevalence and only 9% receiving treatment, tens of millions of American men are living with hormonal deficiency that is measurable, diagnosable, and in many cases directly impacting their quality of life — without ever receiving intervention. The FDA’s 2025 removal of TRT black box cardiovascular warnings, following the 5,246-patient TRAVERSE trial, has changed the clinical calculus decisively. Physicians who previously hesitated to prescribe TRT due to unresolved cardiovascular safety concerns now have definitive trial evidence supporting treatment in appropriate patients, and prescription numbers are already reflecting this shift — the jump from 7.3 million TRT prescriptions in 2019 to 11+ million in 2024 predates the FDA label change, meaning the post-2025 growth curve is likely to be even steeper.

The generational shift in low testosterone is among the most unexpected findings in recent men’s health research. Twenty years ago, low testosterone was almost exclusively discussed as an older man’s problem. The data now shows 20% prevalence among men aged 15–39 and 40% of men under 40 expressing interest in TRT — a demographic and cultural shift that reflects falling testosterone levels in younger cohorts documented by NHANES data going back to 1999, even after controlling for obesity and metabolic factors. The 2022 spike of 27% more TRT patients, including a 58% increase in men aged 35–44 and a 35% increase in men aged 45–54 per PLoS One 2024, confirms that the treatment trend is being driven disproportionately by working-age men in their prime careers — not the elderly population the condition was traditionally associated with.

Normal Testosterone Levels by Age in the US 2026

NORMAL TESTOSTERONE RANGES BY AGE — MEN (ng/dL)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 Age 17–18  ████████████████████████████  300–1,200 ng/dL
 Age 19–39  ████████████████████████      400–950 ng/dL
 Age 40–49  ████████████████████          252–916 ng/dL
 Age 50–59  ██████████████████            215–878 ng/dL
 Age 60–69  ████████████████              196–859 ng/dL
 Age 70+    █████████████                 156–819 ng/dL
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: Baptist Health, AUA Guidelines, Healthline/CDC laboratory data, Highland Longevity (physician-reviewed, 2026), Hone Health, Travison et al. Journal of Clinical Endocrinology & Metabolism

The testosterone level reference data for 2026 reflects a fundamental clinical challenge: the standard laboratory “normal” range of 264–916 ng/dL covers all adult ages together, creating a situation where a 45-year-old man at 280 ng/dL is reported as borderline normal despite having levels that would represent severe decline from his personal peak. The AUA’s recommended optimal treatment target of 450–600 ng/dL is more clinically useful for practitioners, as it reflects the midnormal range where the evidence base for symptom improvement is strongest. Testosterone peaks in the late teens to early 20s at average levels of 600–700 ng/dL, begins its 1–2% annual decline around age 30, and has typically fallen by 20–30% by the 50s and 35–40% by the 70s — numbers confirmed by the landmark Travison et al. population study published in the Journal of Clinical Endocrinology & Metabolism.

The distinction between total testosterone and free testosterone adds another layer of complexity. Total testosterone — the standard clinical measure — includes testosterone bound to proteins (primarily SHBG), while free testosterone is the biologically active fraction immediately available to body tissues. As men age, SHBG levels rise, meaning free testosterone falls faster than total testosterone. This is why JACC research finds that while 25% of men over 65 have low total testosterone, at least 50% of men over 65 have low free testosterone — a doubling of the apparent prevalence simply by changing the measurement. For men in their 40s and 50s with “normal” total testosterone but persistent symptoms, low free testosterone is frequently the undiagnosed culprit, and most standard lab panels do not include the free testosterone measurement unless specifically requested.

Low Testosterone Prevalence by Age Group in the US 2026

LOW TESTOSTERONE PREVALENCE BY AGE — US MEN (2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 Ages 15–39    ████████████████████         20%
 Adults (all)  ████████████████████████     25.7%
 Over 40       ██████████████████████████   Range 12.3/1,000 p-y
 Over 60       ████████████████████         ~20%
 Over 65       ████████████████████         ~25% (total T)
 Over 70       ████████████████████████     ~30%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: PMC/NIH NHANES 2026, AUA Guidelines, JACC, Wiley Online Library, Journal of Endocrine Society 2025, Urology Times

The age-stratified prevalence data for low testosterone in 2026 maps a progression that intensifies steadily across every decade of adult male life, but the data on young men deserves particular emphasis because it defies conventional expectations. The 20% prevalence among 15–39 year-olds — documented through NHANES data and reported in the Journal of Urology — means that approximately one in five young American men already falls below the clinical low testosterone threshold, at ages when hormonal health should theoretically be at or near its peak. This is not a marginal finding in a small study: it is drawn from the National Health and Nutrition Examination Survey, the gold standard for US population health measurement, and it has been replicated across multiple research groups. The implication is that large numbers of American men in their 20s and 30s — dealing with unexplained fatigue, mood changes, difficulty building muscle, or reduced libido — are experiencing measurable testosterone deficiency at an age when clinical guidelines and cultural assumptions would least expect it.

The historical trend of declining prevalence from 28.1% in 2011–12 to 20.3% in 2021–23 in NHANES data is genuine good news, but it requires careful interpretation. The NHANES authors note that this trend may reflect changes in population composition, measurement methodology, or genuine improvements in metabolic health risk factors over the period — and they explicitly caution that “causal attribution of changes over time is not possible with repeated cross-sectional data.” What the trend does confirm is that testosterone deficiency is not an inevitably worsening epidemic: lifestyle factors, metabolic health management, and population-level interventions can and do make a measurable difference in prevalence rates, suggesting that obesity reduction, physical activity promotion, and sleep quality improvement could all contribute to further declines in the coming years.

Low Testosterone Symptoms & Health Impact Statistics in the US 2026

LOW TESTOSTERONE SYMPTOM PREVALENCE — KEY DATA (2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 Decreased libido        █████████████████████████  Most common
 Fatigue / low energy    █████████████████████████  Most common
 Erectile dysfunction    ████████████████████████   Very common
 Reduced muscle mass     ████████████████████       Common
 Increased body fat      ████████████████████       Common
 Depression/mood change  ███████████████████        Common
 Bone density loss       ██████████████             Significant risk
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: AUA Guidelines, PMC/NIH NHANES April 2026, Wiley Online Library, JACC, Journal of Clinical Endocrinology & Metabolism, Exploration Endocrinology & Metabolism 2024, Cleveland Clinic

The clinical consequences of low testosterone extend dramatically beyond sexual health, and the 2024–2026 research literature documents health outcomes that reframe testosterone deficiency as a serious systemic condition rather than a lifestyle inconvenience. The European Male Ageing Study (EMAS) analysis of 2,599 men aged 40–79, published in Exploration Endocrinology & Metabolism (2024), found that men with three or more hypogonadal symptoms combined with low testosterone levels faced a 3.8-fold higher cardiovascular disease mortality risk and a 3.1-fold higher all-cause mortality risk over a median 4.3-year follow-up — risk ratios that would trigger urgent intervention in any other disease category. The AUA has elevated low testosterone to a formal cardiovascular risk factor, carrying a Strong Recommendation at Grade B evidence level, meaning the association between testosterone deficiency and cardiovascular disease is now considered clinically established rather than merely associative.

The obesity-testosterone bidirectional relationship is one of the most clinically significant findings from the 2026 NHANES analysis. Low testosterone promotes adipose tissue accumulation through multiple metabolic pathways, while simultaneously, obesity and the associated inflammatory state suppress hypothalamic-pituitary-gonadal axis activity, lowering testosterone production further. This creates a physiological feedback loop where each condition worsens the other — and it is one of the primary reasons the NHANES researchers identified obesity and impaired glucose regulation as the strongest modifiable predictors of testosterone deficiency in their 2026 analysis. Breaking this cycle — whether through weight loss, exercise, metabolic health management, or TRT — has measurable downstream effects on both hormonal and metabolic outcomes, which is part of why clinical interest in treating testosterone deficiency as a metabolic disorder rather than purely a sexual health issue has grown substantially in the 2024–2026 medical literature.

Testosterone Replacement Therapy (TRT) Statistics in the US 2026

TRT MARKET & PRESCRIPTION TRENDS — US 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 TRT Rx 2019      █████████████           7.3 Million
 TRT Rx 2024      █████████████████████   11+ Million
 Global TRT 2024  ██████████████          $1.63 Billion
 Global TRT 2026  █████████████████       $2.13 Billion
 Global TRT 2033  ████████████████████████ $3.51 Billion
 North America    ████████████████████████ 47.6% of market
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: CBS News 2025, PLoS One 2024, Mordor Intelligence 2026, SkyQuestT, Journal of Urology 2024, SingleCare 2025, Reanin

The US TRT prescription trajectory — from 7.3 million in 2019 to 11+ million in 2024 — represents a 50.7% increase in just five years and reflects the convergence of several market forces: growing awareness of testosterone deficiency symptoms among younger men, the expansion of telehealth platforms offering remote hormone testing and e-prescription services, significant direct-to-consumer marketing by men’s health clinics, and critically, the 2025 FDA removal of cardiovascular black box warnings from TRT products following the TRAVERSE trial. With barriers to prescribing now lower than at any point in TRT’s history, the prescription trajectory is likely to accelerate further through 2026 and beyond. The 47.6% North American share of the global TRT market confirms the United States as the dominant driver of worldwide testosterone therapy demand, and with injectable formulations holding 54.7% of market share due to physician familiarity and lower cost, injectables remain the clinical workhorse even as oral capsule formulations grow at 5.57% annually — the fastest-growing delivery segment as newer oral testosterone products gain prescriber acceptance.

The regional distribution of TRT growth in the US tells its own story. The South’s 52% increase in TRT patients between 2018 and 2022 — the largest of any US region — reflects both the higher prevalence of obesity and metabolic syndrome in Southern states (risk factors that directly suppress testosterone) and the denser network of men’s health and TRT clinic franchises that have expanded aggressively in the Sun Belt. The Midwest showing zero increase in the same period is the statistical outlier that deserves further research, though it may reflect a combination of different demographic composition, lower telehealth adoption rates, and fewer independent men’s health clinic operators in the region. The average 4.2% annual decline in TRT prices between 2018 and 2022 — documented by the Journal of Urology — has made treatment progressively more accessible to men paying out-of-pocket, while the majority of medically necessary TRT prescriptions are covered by insurance when properly documented.

Low Testosterone Risk Factors & Causes Statistics in the US 2026

LOW TESTOSTERONE RISK FACTOR SIGNIFICANCE — US MEN (2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 Obesity / High BMI        ████████████████████████  Strongest predictor
 Impaired glucose/Diabetes ████████████████████████  Strong predictor
 Sedentary behavior        ████████████████████      Significant risk factor
 Aging (30+ years)         ████████████████████████  1–2% annual decline
 Sleep disorders            ████████████████          Significant association
 Chronic stress             ██████████████            Cortisol suppression
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: PMC/NIH NHANES April 2026, Wiley Online Library, Travison et al. JCEM, Highland Longevity, Urology Times, ScienceDirect

The risk factor data from the 2026 NHANES analysis carries direct actionable implications for men’s health at a population level. Obesity and impaired glucose regulation were identified as the strongest modifiable predictors of testosterone deficiency across all four NHANES cycles (2011–2016 and 2021–2023), confirming that the most effective public health intervention for testosterone deficiency at scale is not hormonal treatment — it is metabolic health management. The authors of the April 2026 PMC/NIH study explicitly describe the relationship as bidirectional: low testosterone promotes adiposity and insulin resistance, while these same metabolic conditions suppress the hypothalamic-pituitary-gonadal axis and reduce testosterone production. This feedback loop explains why men who lose significant body weight often experience meaningful testosterone recovery without any direct hormonal intervention, and why treating obesity in testosterone-deficient men can reduce or eliminate the clinical indication for TRT.

The persistence of testosterone decline in young men even after controlling for BMI — documented in the NHANES data covering 1999–2016 and confirmed by ScienceDirect — is the finding that most challenges the conventional risk-factor narrative. If testosterone levels in 15–39 year-olds are falling over time even among men of normal weight, then factors beyond obesity and metabolic syndrome must be contributing to the trend. Research has pointed to endocrine-disrupting chemicals in plastics and personal care products, chronic sleep disruption from screen use and shift work, chronic psychological stress, and declining physical activity levels as likely contributors — none of which is fully captured by BMI or glucose measurements. The sedentary behavior finding in the 2026 NHANES analysis — identifying physical inactivity as a significant independent risk factor — is consistent with the hypothesis that reduced muscle-demanding activity in daily life has downstream effects on the hormonal systems that regulate testosterone production.

Low Testosterone Awareness & Diagnosis Gap Statistics in the US 2026

TESTOSTERONE DIAGNOSIS GAP — KEY METRICS (2026)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 Prevalence (US men)      ████████████████████████  25.7%
 Currently Treated         ██                        ~9%
 Treatment Gap             ████████████████████████  ~16.7%
 Awareness of Symptoms     ████████████████          Variable
 Men Formally Diagnosed    ░░                        ~5% (some studies)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Data sources: Transparency Market Research, BMJ Open July 2025, US Pharmacist June 2025, Cleveland Clinic, Endocrine Society

The gap between testosterone deficiency prevalence and treatment rates is the defining inefficiency of men’s hormonal healthcare in 2026. With 25.7% prevalence and only ~9% receiving treatment, the vast majority of testosterone-deficient American men remain undiagnosed and untreated — a situation that the BMJ Open study from July 2025 (surveying 973 community-dwelling men) quantifies with uncomfortable precision. In that study, 49% of men showed high-likelihood testosterone deficiency symptoms by validated questionnaire, but only 5% had been formally diagnosed — a tenfold gap between those who probably have the condition and those who have been clinically identified. The 55% of men who were unfamiliar with the symptoms of testosterone deficiency confirms that the awareness problem is structural and ongoing, not a product of inadequate medical access alone.

The practical consequence of this awareness gap is that the most common symptoms of testosterone deficiency — fatigue, decreased libido, mood changes, difficulty maintaining muscle mass, and weight gain — are among the most easily misattributed in all of medicine. They overlap substantially with depression, normal aging, sleep disorders, and work-related burnout, meaning that men experiencing these symptoms frequently receive treatment for the secondary presentation rather than the underlying hormonal deficiency. The AUA’s clinical guideline that diagnosis requires both low serum testosterone AND relevant symptoms is clinically sound, but it depends on practitioners making the connection between a patient’s non-specific complaints and the possibility of hormonal deficiency — a connection that the BMJ Open data suggests is being missed in the overwhelming majority of cases. The FDA’s 2025 removal of the TRT cardiovascular black box warning removes one of the most significant prescriber-side barriers, but closing the ~16.7 percentage point gap between prevalence and treatment requires equally significant progress on the patient awareness and primary care recognition sides of the equation.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE